Navigation Links
Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections
Date:9/9/2010

>

(2) The 2003 Gallup Study of Women's Yeast Infection Treatment Products [p. 96]

(3) A product of Combe Incorporated. The trademarks use herein are trademarks of their respective owners.

(4) A product of Combe Incorporated. The trademarks use herein are trademarks of their respective owners.

About MONISTAT®

MONISTAT®, which means "stops yeast infections," is an over-the-counter, antifungal yeast infection treatment that relieves symptoms and cures the infection.  The Brand offers a portfolio of products, including 1-, 3- and 7-Day treatments, which are available in three forms – OVULE®, cream and suppository – and are designed to help women confidently address their vaginal health needs on their terms. The active ingredient in MONISTAT® is Miconazole Nitrate.  For a complete list of MONISTAT® products, visit www.monistat.com.  MONISTAT® is a brand of McNEIL-PPC, Inc.

About the Survey

This MONISTAT® Survey was conducted by Wakefield Research among 711 nationally representative American women aged 18 to 24, using an email invitation and an online survey between June 4th and June 9th, 2010. Quotas were set to ensure reliable and accurate representation of the total U.S. population of women 18-24 year olds.

Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the 711 interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.68 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.

This press release contains "forward-looking st
'/>"/>

SOURCE The MONISTAT(R) Brand
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
2. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
3. Hot Times in the City: As Summer Temperatures Soar, Pulse of Passion Survey Reveals What Makes Americans Sizzle in Relationships
4. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
5. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
6. Reportlinker Adds U.S. Market for Hearing Aids and Audiology Devices 2010 (Includes Audiologist Survey)
7. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
8. Partnership for a Drug-Free Americas 21st Annual Teen Survey Shows No Significant Increase in Over-the-Counter Medicine Abuse Rates
9. New Survey Shows Seniors Struggle Under the Weight of Multiple Medication Use
10. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
11. Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and administration of cell therapies, today said that it ... Platform (AXP) used for the processing of cord blood. ... in the country later this year. "We ...
... Mass., May 22, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, announced today that it has received ... serving the muscular dystrophy patient community. Halo will ... study of HT-100, its lead drug candidate for ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... 2014 CBPartners, a global leader in ... a new website. The redesigned site boasts improved ... to the firm’s thought pieces, blog posts, and conference ... to showcase our insights, capabilities, and to provide timely ... Executive Officer, Cyrus Chowdhury. “An enhanced online presence ...
(Date:7/10/2014)... Best Drug Rehabilitation , which ... close by during a stay in rehab can ... the process is successful, has launched an inspiring ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories section ... Best Drug Rehabilitation graduates who wanted to help ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
(Date:7/10/2014)... new study from Colorado School of Public Health shows ... a major problem in the Navajo Nation and among ... Americans is abysmal with more than three times the ... Batliner, DDS, MBA, associate director of the Center for ... Health. "The number one problem is access to care." ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Study finds widespread oral health problems among Navajo 2
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and manufacturer of ... its financial results for the first quarter,ended March ... the first,quarter of 2008, as compared with $5.2 ... in the first quarter 2008 include wound care ...
... DALLAS, May 6 Claimsnet.com inc. (OTC,Bulletin Board: ... healthcare industry, today reported,its results for the first quarter ... the quarter ended March 31, 2008, the Company reported ... for the first quarter,of 2007., Expenses overall, comprised ...
... U.S. college students are smoking tobacco using waterpipes or ... according to a new study led by a Virginia Commonwealth ... prevalence and perceptions related to waterpipe tobacco smokers and are ... Health. The article is also featured in an editorial in ...
... alleviate the plaguing symptoms of allergies ... and asthma, ... allergies or asthma while outdoors, but why deal with irritating,triggers in your home? ... focus on more important things, not on your,symptoms., Try to prevent as ...
... Acquisition of dermal filler product enhances company,s aesthetic ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical company ... ABR Invent and ABR,Development, developers of the dermal ... of ABR Invent and ABR Development,through a definitive ...
... mole develops into melanoma by showing the interaction of ... The Penn State scientists also demonstrate that therapeutic ... effectively treat this deadly form of cancer. , "We ... Akt3 communicate with one another in a mole, ...
Cached Medicine News:Health News:NUCRYST Announces First Quarter 2008 Financial Results 2Health News:NUCRYST Announces First Quarter 2008 Financial Results 3Health News:NUCRYST Announces First Quarter 2008 Financial Results 4Health News:NUCRYST Announces First Quarter 2008 Financial Results 5Health News:NUCRYST Announces First Quarter 2008 Financial Results 6Health News:NUCRYST Announces First Quarter 2008 Financial Results 7Health News:Claimsnet.com Reports First Quarter 2008 Results 2Health News:Claimsnet.com Reports First Quarter 2008 Results 3Health News:Waterpipe smoking on college campuses may contribute to growing public health problem 2Health News:Double Trouble: Fight Allergy and Asthma in Your Home 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 2Health News:Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development 3Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: